Morgan D J, Bray K M
Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, Melbourne, Victoria, Australia.
Clin Pharmacokinet. 1994 Apr;26(4):292-307. doi: 10.2165/00003088-199426040-00005.
There is mounting evidence to suggest that lean body mass (LBM) may be a better predictor of drug dosage than either total bodyweight (TBW) or body surface area (BSA), although the rationale for this is not clear. LBM, which is similar but not identical to fat-free mass, can be determined by many different methods. A simple equation based on TBW and height, or determination by bioelectrical impedance are probably the most suitable for use in drug disposition studies. Volume of distribution of relatively hydrophilic drugs correlates very well with LBM, with correlation coefficients of up to 0.9. LBM can be used to accurately predict the loading dose required for these drugs to attain a target peak plasma concentration. For lipophilic drugs, volume of distribution correlates better with TBW than with LBM. Investigation of the relationship between renal drug clearance and LBM has received little attention, probably because creatinine clearance is a useful and readily available marker of renal function. However, limited data suggest that creatinine clearance and LBM together may account function. However, limited data suggest that creatinine clearance and LBM together may account for more variability in renal clearance than creatinine clearance alone. For many drugs eliminated predominantly by the liver, there is a good correlation between systemic clearance and LBM. Such a correlation could be due to a correlation between systemic clearance and liver size or liver blood flow, which has been demonstrated for a few drugs, and a correlation between LBM and liver size and blood flow. The presence of a relationship between LBM and organ size and blood flow has, however, not been investigated to date. A good correlation between drug clearance and LBM indicates that LBM may be an accurate predictor of maintenance dosage, especially in obese patients, in whom there is a large discrepancy between LBM and TBW. BSA is an accurate predictor of drug dosage in infants and children, but whether LBM is superior to BSA in this population remains to be determined. In most studies in adults in which dosage based on LBM has been evaluated prospectively, LBM has been shown to be superior to other measures of body size as a predictor of drug dosage.
越来越多的证据表明,瘦体重(LBM)可能比总体重(TBW)或体表面积(BSA)更能准确预测药物剂量,尽管其原理尚不清楚。LBM与去脂体重相似但并不完全相同,可通过多种不同方法测定。基于TBW和身高的简单公式或生物电阻抗测定法可能最适合用于药物处置研究。相对亲水性药物的分布容积与LBM的相关性非常好,相关系数高达0.9。LBM可用于准确预测这些药物达到目标血浆峰浓度所需的负荷剂量。对于亲脂性药物,分布容积与TBW的相关性优于与LBM的相关性。关于肾药物清除率与LBM之间关系的研究很少受到关注,可能是因为肌酐清除率是肾功能的一个有用且易于获得的指标。然而,有限的数据表明,肌酐清除率和LBM共同作用可能比单独的肌酐清除率更能解释肾清除率的变异性。对于许多主要经肝脏消除的药物,全身清除率与LBM之间存在良好的相关性。这种相关性可能是由于全身清除率与肝脏大小或肝血流量之间的相关性(已在少数药物中得到证实),以及LBM与肝脏大小和血流量之间的相关性。然而,迄今为止尚未研究LBM与器官大小和血流量之间关系的存在情况。药物清除率与LBM之间的良好相关性表明,LBM可能是维持剂量的准确预测指标,尤其是在肥胖患者中,LBM与TBW之间存在很大差异。BSA是婴儿和儿童药物剂量的准确预测指标,但在该人群中LBM是否优于BSA仍有待确定。在大多数对基于LBM的剂量进行前瞻性评估的成人研究中,LBM已被证明作为药物剂量的预测指标优于其他身体大小指标。